PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
PharmAla To Supply Amsterdam UMC with LaNeo MDMA, Including Development of New Single-Capsule Stability Data
Goldgroup Announces Shareholder Approval of Arrangement with Gold Resource Corporation and Results of Annual General and Special Meeting
Freegold Drills 2.08 g/t Au over 62.1 m within 102.3 m of 1.67 g/t Au in Infill Drilling at Golden Summit
Metalsource Mining Expands Silver Hill District Through Strategic Land Acquisition as Exploration Footprint Continues to Grow
